Edwards Lifesciences Corp. (NYSE:EW) shot up 0.8% on Tuesday . The stock traded as high as $100.20 and last traded at $99.38, with a volume of 613,469 shares traded. The stock had previously closed at $98.58.

EW has been the topic of a number of research analyst reports. BTIG Research raised Edwards Lifesciences Corp. from a “neutral” rating to a “buy” rating and set a $115.00 price target on the stock in a report on Saturday, April 2nd. JMP Securities reissued a “mkt perform” rating on shares of Edwards Lifesciences Corp. in a report on Wednesday, June 1st. Royal Bank Of Canada reissued an “outperform” rating and set a $125.00 price target (up from $110.00) on shares of Edwards Lifesciences Corp. in a report on Wednesday, April 27th. Leerink Swann reissued a “buy” rating and set a $125.00 price target (up from $115.00) on shares of Edwards Lifesciences Corp. in a report on Wednesday, April 27th. Finally, Canaccord Genuity reissued a “buy” rating and set a $132.00 price target on shares of Edwards Lifesciences Corp. in a report on Wednesday, June 1st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have given a buy rating to the company. Edwards Lifesciences Corp. presently has a consensus rating of “Buy” and an average target price of $106.14.

The company has a market cap of $21.92 billion and a price-to-earnings ratio of 44.06. The firm’s 50-day moving average price is $99.58 and its 200 day moving average price is $92.31.

Edwards Lifesciences Corp. (NYSE:EW) last released its quarterly earnings data on Tuesday, April 26th. The medical research company reported $0.71 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. The company earned $697.30 million during the quarter, compared to the consensus estimate of $664.53 million. The company’s revenue for the quarter was up 18.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.12 EPS. On average, analysts predict that Edwards Lifesciences Corp. will post $2.77 earnings per share for the current fiscal year.

In other Edwards Lifesciences Corp. news, VP Patrick B. Verguet sold 7,000 shares of the business’s stock in a transaction dated Monday, May 2nd. The stock was sold at an average price of $106.86, for a total value of $748,020.00. Following the completion of the transaction, the vice president now directly owns 115,107 shares of the company’s stock, valued at $12,300,334.02. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Michael A. Mussallem sold 59,000 shares of the business’s stock in a transaction dated Friday, April 29th. The shares were sold at an average price of $106.13, for a total value of $6,261,670.00. Following the completion of the transaction, the chief executive officer now directly owns 79,256 shares of the company’s stock, valued at $8,411,439.28. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have bought and sold shares of the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in Edwards Lifesciences Corp. by 104.0% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,094 shares of the medical research company’s stock worth $1,113,000 after buying an additional 7,186 shares during the last quarter. Bank of Hawaii boosted its position in Edwards Lifesciences Corp. by 99.5% in the fourth quarter. Bank of Hawaii now owns 14,640 shares of the medical research company’s stock worth $1,156,000 after buying an additional 7,300 shares during the last quarter. Navellier & Associates Inc boosted its position in Edwards Lifesciences Corp. by 82.2% in the fourth quarter. Navellier & Associates Inc now owns 17,295 shares of the medical research company’s stock worth $1,366,000 after buying an additional 7,805 shares during the last quarter. Alpine Woods Capital Investors LLC boosted its position in Edwards Lifesciences Corp. by 67.1% in the fourth quarter. Alpine Woods Capital Investors LLC now owns 20,312 shares of the medical research company’s stock worth $1,604,000 after buying an additional 8,156 shares during the last quarter. Finally, Andra AP fonden boosted its position in Edwards Lifesciences Corp. by 30.1% in the fourth quarter. Andra AP fonden now owns 39,800 shares of the medical research company’s stock worth $3,143,000 after buying an additional 9,200 shares during the last quarter.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.